<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01996761</url>
  </required_header>
  <id_info>
    <org_study_id>2010-09-084-001</org_study_id>
    <nct_id>NCT01996761</nct_id>
  </id_info>
  <brief_title>Effects of Cerebrolysin on Motor Recovery in Patients With Subacute Stroke</brief_title>
  <acronym>E-COMPASS</acronym>
  <official_title>Effects of Cerebrolysin on Motor Recovery in Patients With Subacute Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <brief_summary>
    <textblock>
      This study, E-COMPASS is a phase IV clinical trial designed as a multicenter, randomized,&#xD;
      double-blind, placebo-controlled, parallel-group study. This study will enroll 75 subacute&#xD;
      stroke patients with unilateral motor dysfunction. Primary objective is to demonstrate the&#xD;
      efficacy of porcine brain peptide to improve motor recovery measured by the improvement ratio&#xD;
      of Fugl-Meyer assessment ((score of FMA after 3 weeks - score of FMA at baseline) / score of&#xD;
      FMA at baseline) in patients with subacute stroke.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the improvement ratio of Fugl-Meyer assessment</measure>
    <time_frame>after 3 weeks</time_frame>
    <description>Primary objective is to demonstrate the efficacy of porcine brain peptide to improve motor recovery measured by the improvement ratio of Fugl-Meyer assessment ((score of FMA after 3 weeks - score of FMA at baseline) / score of FMA at baseline) in patients with subacute stroke</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Cerebrolysin</condition>
  <arm_group>
    <arm_group_label>Study Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study Group 1: 30ml Cerebrolysin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Study Group 2: Placebo (0.9% NaCl)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>porcine brain peptide (Cerebrolysin)</intervention_name>
    <arm_group_label>Study Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Study Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 1st cortical or subcortical unilateral infarction (supratentorial lesion)&#xD;
&#xD;
          2. Confirmed by CT or MRI&#xD;
&#xD;
          3. Subacute stage: less than 1 week&#xD;
&#xD;
          4. Moderate to severe motor function involvement-total of FMA: 0-84&#xD;
&#xD;
          5. Age: between 18 and 80 years&#xD;
&#xD;
          6. Inpatients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Progressive or unstable stroke&#xD;
&#xD;
          2. Pre-existing and active major neurological disease&#xD;
&#xD;
          3. Pre-existing and active (e.g., on chronic medication) major psychiatric disease, such&#xD;
             as major depression, schizophrenia, bipolar disease, or dementia&#xD;
&#xD;
          4. A history of significant alcohol or drug abuse in the prior 3 years&#xD;
&#xD;
          5. Advanced liver, kidney, cardiac, or pulmonary disease&#xD;
&#xD;
          6. A terminal medical diagnosis consistent with survival &lt; 1 year&#xD;
&#xD;
          7. Substantial decrease in alertness at the time of randomization, defined as score of 2&#xD;
             on NIH Stroke Scale&#xD;
&#xD;
          8. Pregnancy or lactating; note that a negative pregnancy test will be required if the&#xD;
             patient is a female in reproductive years&#xD;
&#xD;
          9. Any condition that would represent a contraindication to Cerebrolysin, including&#xD;
             allergy to Cerebrolysin&#xD;
&#xD;
         10. Current enrolment in another therapeutic study of stroke or stroke recovery&#xD;
&#xD;
         11. Total serum bilirubin &gt; 4 mg/dL, alkaline phosphatase &gt; 250 U/L, SGOT/AST &gt; 150 U/L,&#xD;
             SGPT/ALT &gt; 150 U/L, or creatinine &gt; 3.5 mg/dL; or cardiopulmonary deficits large&#xD;
             enough to interfere with reasonable participation in physiotherapy during the trial.&#xD;
&#xD;
         12. Previous porcine brain peptide administration history&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>November 5, 2013</study_first_submitted>
  <study_first_submitted_qc>November 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2013</study_first_posted>
  <last_update_submitted>May 10, 2016</last_update_submitted>
  <last_update_submitted_qc>May 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Yun-Hee Kim</investigator_full_name>
    <investigator_title>Yun-Hee Kim</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebrolysin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

